Highlights

• Group underlying revenue increased 6.2% to AU$3.82 billion, supported by pricing and insurance portfolio growth.
• Underlying operating profit rose 9.1% to AU$260.90 million despite continued claims and affordability pressures.
• FY26 dividends reached 34.0 cents per share, including a 5.0-cent special dividend.

nib Holdings Reports Higher FY26 Operating Earnings

nib holdings limited (ASX: NHF) announced its FY26 financial results on 21 August 2026, covering the 12 months ended 30 June 2026. The health insurer delivered stronger underlying operating earnings despite elevated healthcare costs, cost-of-living pressures and a more demanding regulatory environment.

Group underlying revenue increased 6.2% to AU$3.82 billion, compared to AU$3.60 billion in FY25. Underlying operating profit advanced 9.1% to AU$260.90 million, while statutory operating profit rose 8.6% to AU$215.70 million. However, net profit after tax declined 5.9% to AU$186.90 million, partly reflecting lower investment income and higher one-off, acquisition and integration expenses.

Health Insurance Businesses Deliver Mixed Performance

Australian residents health insurance remained nib’s largest earnings contributor. Insurance revenue increased 6.4% to AU$3,012.70 million, although underlying operating profit fell 9.6% to AU$187.90 million as claims costs remained elevated. Policyholder growth reached 1.9%.

International inbound health insurance produced stronger earnings, with underlying operating profit increasing 15.1% to AU$35.10 million. New Zealand operations also improved materially, recording underlying operating profit of AU$27.50 million compared with a AU$2.90 million loss in FY25.

Health Services Reaches Profitability

nib Health Services achieved its full-year profit, generating underlying operating profit of AU$2.40 million, compared with a AU$5.90 million loss previously. Operating income increased 46.0%, supported by full ownership of Honeysuckle Health and operating efficiencies.

Dividend Increases as Capital Position Strengthens

The Board declared a 21.0-cent fully franked final dividend, including a 5.0-cent special dividend. This lifted total FY26 dividends to 34.0 cents per share, up 17.2% from FY25. The final dividend is due to be distributed to shareholders on 7 October 2026. nib also ended FY26 with gearing reduced to 15.2% and a leverage ratio of 0.6 times, providing financial flexibility as the Group focuses on core health insurance, digital capability, AI and health services.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au